RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $123
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev maintains an Outperform rating on Axsome Therapeutics (NASDAQ:AXSM) but lowers the price target from $126 to $123.

February 21, 2024 | 3:09 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital maintains an Outperform rating on Axsome Therapeutics but lowers the price target from $126 to $123.
The adjustment in price target by RBC Capital, while maintaining an Outperform rating, suggests a slight recalibration of expectations rather than a fundamental shift in the company's outlook. The reduction in price target is relatively minor, indicating that the analyst's long-term view on the company remains positive. This could lead to a neutral short-term impact on the stock as investors digest the minor adjustment in valuation expectations.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100